Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705575 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 688
- Enrollment target
NCT00705575 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 688 participants.
The verdict
NCT00705575, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 688 participants
- Enrollment target
Study Summary
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.
Interventions
- DRUG Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
- DRUG Aliskiren (300 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00705575
The ClinicalTrials.gov registry entry for NCT00705575 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 688 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg) is the first listed.
NCT00705575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00705575 about?
NCT00705575 is a clinical study titled "Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension". This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.
What is the current status of trial NCT00705575?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 688 participants. The study started on 2008-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00705575?
The interventions under investigation include: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg) (DRUG), Aliskiren (300 mg) (DRUG).
Who is sponsoring clinical trial NCT00705575?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.